Steven Chance for Oxford Brain Diagnostics, Ltd

Oxford Brain Diagnostics Ltd

Founded in neuropathological and neuroimaging expertise, the company’s patented Cortical Disarray Measurement (CDM®) technology uses MRI brain scan data to support early and differential diagnosis, track progression, and predict the decline of neurodegenerative diseases. Oxford Brain Diagnostics is committed to assessing brain health based on changes in the cellular structure, supporting drug development, and helping clinicians around the world in their fight to defeat Alzheimer’s and other neurodegenerative diseases. The CDM® software device can be used as an adjunct to other diagnostics evaluations, intended to predict conversion from Mild Cognitive Impairment to Alzheimer’s Disease in patients previously diagnosed with MCI.

Other Presentations

Aevum – Gail Chan, PhD – View


AKScientist – Aarti Kuver, PhD – View


AmyloiDia – Vladana Vukojevic, PhD View


ASDERA LLC – Knut Wittkowski, PhD – View


BIORCHESTRA Co., Ltd – Branden Ryu, PhD – View


BioTrillion, Inc. – Savan Devani, MS – View


BrainCures – Krzysztof Potempa, PhD – View


BrainTrip – Jurij Dreo, MD – View


Diadem – Simona Piccirella, PhD – View


Generian Pharmaceuticals, Inc. – Toren Finkel, MD, PhD – View


Lauren Sciences LLC – Susan Rosenbaum, JD –View


LumeNeuro – Ron Dennis – View


Marvel Biotechnology – Mark Williams, PhD, MBA – View


Memandis – Nareem Surya View


MGH/Harvard Medical School – Xudong Huang, PhD – View


Neuropath Therapeutics Limited – Julie Kelly, PhD – View


University of Haifa – Nathaniel Gould, PhD – View


Winterlight Labs – Nicola Johnson, MS – View